JAK2V617F and phenotype: Questions galore

Blood

Volumn 109, Issue 1, 2007, Pages 8-

  Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; BUDD CHIARI SYNDROME; COHORT ANALYSIS; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC SCREENING; HUMAN; INCIDENCE; LEUKOCYTOSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NOTE; PATIENT SELECTION; PHENOTYPE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; THROMBOCYTOSIS; THROMBOPHILIA; ZYGOSITY;

EID: 33846015790     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-050914     Document Type: Note

References (4)

1. Sidon P, El Housni H, Dessars B, Heimann P. The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia. 2006;20:1622.
2. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia. 2006;20:168-171.
3. Tefferi A, Lasho TL, Gilliland G. JAK2 mutations in myeloproliferative disorders [letter]. N Engl J Med. 2005;353:1416-1417.
4. Pardanani AD, Levine RL, Lasho T, Pikman Y, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.